Literature DB >> 10502048

Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) and its receptor flt-1 in microcystic meningiomas.

C Christov1, E Lechapt-Zalcman, H Adle-Biassette, S Nachev, R K Gherardi.   

Abstract

We investigated the immunohistochemical expression of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) and of its endothelial cell receptor flt-1 in relationship to microcyst formation in meningiomas. Expression of VPF/VEGF was studied in 60 meningiomas (6 microcystic, 38 partially microcystic and 16 with no microcystic areas) and 30 meningiomas from these three subgroups were evaluated for flt-1 expression. VPF/VEGF immunoreactivity was mainly observed in vessel endothelium. Positive vessels were present in 75% (33/44) of meningiomas with any amount of microcystic pattern and in 38% (6/16) of the solid meningiomas (P < 0.02). Densities and percentages of both VPF/VEGF-positive and flt-1-positive vessels were higher in meningiomas with microcystic areas than in solid meningiomas (P </= 0.002). The 6 microcystic meningiomas showed the highest densities and percentages of both VPF/VEGF-positive (P </= 0.0002) and flt-1-positive vessels (P </= 0. 01). Vessel expression of VPF/VEGF and flt-1 were positively correlated (r >/= 0.75, P < 0.0001). A strong positive correlation between VPF/VEGF-positive vessel density and proportion of microcystic pattern in all 60 specimens was found (r = 0.75, P < 0. 0001). We conclude that accumulation of flt-1-bound VPF/VEGF on endothelial cells of meningiomas is associated with microcyst formation that leads to the histologic appearance of microcystic meningiomas.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10502048     DOI: 10.1007/s004010051102

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  8 in total

1.  p-CREB expression in human meningiomas: correlation with angiogenesis and recurrence risk.

Authors:  Valeria Barresi; Giovanni Branca; Maria Caffo; Giovanni Tuccari
Journal:  J Neurooncol       Date:  2015-01-07       Impact factor: 4.130

Review 2.  VEGF in brain tumors.

Authors:  M R Machein; K H Plate
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.130

3.  The relationship between peritumoral brain edema and the expression of vascular endothelial growth factor and its receptors in intracranial meningiomas.

Authors:  Shinji Otsuka; Takashi Tamiya; Yasuhiro Ono; Hiroyuki Michiue; Kazuhiko Kurozumi; Shigeru Daido; Hirokazu Kambara; Isao Date; Takashi Ohmoto
Journal:  J Neurooncol       Date:  2004-12       Impact factor: 4.130

4.  MMP-9 expression in meningiomas: a prognostic marker for recurrence risk?

Authors:  V Barresi; E Vitarelli; G Tuccari; G Barresi
Journal:  J Neurooncol       Date:  2010-07-21       Impact factor: 4.130

5.  Semaphorin3A immunohistochemical expression in human meningiomas: correlation with the microvessel density.

Authors:  Valeria Barresi; Enrica Vitarelli; Serenella Cerasoli
Journal:  Virchows Arch       Date:  2009-03-19       Impact factor: 4.064

6.  Factors affecting peritumoral brain edema in meningioma: special histological subtypes with prominently extensive edema.

Authors:  Tadashi Osawa; Masahiko Tosaka; Masaya Nagaishi; Yuhei Yoshimoto
Journal:  J Neurooncol       Date:  2012-10-27       Impact factor: 4.130

7.  A multi-institutional phase II trial of bevacizumab for recurrent and refractory meningioma.

Authors:  Priya Kumthekar; Sean Aaron Grimm; Roxanne T Aleman; Marc C Chamberlain; David Schiff; Patrick Y Wen; Fabio Massaiti Iwamoto; Demirkan Besim Gursel; David A Reardon; Benjamin Purow; Masha Kocherginski; Irene Helenowski; Jeffrey J Raizer
Journal:  Neurooncol Adv       Date:  2022-08-19

8.  Vascular endothelial growth factor signals through platelet-derived growth factor receptor β in meningiomas in vitro.

Authors:  C Pfister; H Pfrommer; M S Tatagiba; F Roser
Journal:  Br J Cancer       Date:  2012-10-09       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.